Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
about
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuationThe use of natalizumab for multiple sclerosisSwitching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSRisk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.Safety concerns and risk management of multiple sclerosis therapies.Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
P2860
Q33562198-E8F325F4-F90E-4686-8B36-99D97413106BQ33879159-9960F910-6BCD-46ED-88FA-84AFB19DB4B1Q35850708-6BB0BAA7-8779-48E9-BC6C-7297F245A8ACQ37380300-7B657C9F-EC47-4061-A4CB-B97AD69B2C7FQ38665413-3424397D-B3C7-4350-BE4F-F8251D53AF81Q39021781-371BF89E-D1C9-4B8A-8972-F78D2A75D20CQ40747927-C98FF517-6E54-4F33-A960-9DA6F741DDBCQ41002593-D57E0D07-EA06-442B-A14C-69B3B1F72617Q52142630-BDF6DD08-1026-4923-80AA-36FC70D89B19Q53140129-678C34A0-F45C-48FF-BF3F-48B77C8853A1Q58793277-E50B1D8B-4FA4-4771-BEF7-6D9511D1BA0B
P2860
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@en
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@nl
type
label
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@en
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@nl
prefLabel
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@en
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
@en
P2093
Antoine Gueguen
Caroline Bensa
Françoise Heran
Julien Savatovsky
Olivier Gout
Pascal Roux
Romain Deschamps
P2860
P304
P356
10.1136/JNNP-2014-307591
P407
P577
2014-05-29T00:00:00Z